Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations

Franziska Kluwe, Robin Michelet, Anna Mueller-Schoell, Corinna Maier, Lena Klopp-Schulze, Madelé van Dyk, Gerd Mikus, Wilhelm Huisinga, Charlotte Kloft

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)

    Abstract

    Drug approval is based on exposure, response, and variability of studied populations, typically excluding comorbidities/medications and very ill patients, thus not representing real-world populations. This results in wide variability in therapeutic outcome for individual patients. Model-informed precision dosing
    (MIPD) can characterize/quantify this variability, support optimal dose selection, and enable individualized therapy. The aim of this perspective is to raise awareness for MIPD, identify challenges hindering its implementation in clinical practice, provide recommendations, and highlight opportunities.
    Original languageEnglish
    Pages (from-to)29-36
    Number of pages8
    JournalClinical Pharmacology and Therapeutics
    Volume109
    Issue number1
    Early online date17 Oct 2020
    DOIs
    Publication statusPublished - Jan 2021

    Fingerprint Dive into the research topics of 'Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations'. Together they form a unique fingerprint.

    Cite this